Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00758251
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
- Signed and dated Patient Informed Consent (ICF)
Read More
Exclusion Criteria
- Hypersensitivity to the active substance or to any of the excipients of Seroquel XR
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in CGI scores and BPRS comparing visits 1 and 3. twice with 4 week interval
- Secondary Outcome Measures
Name Time Method To evaluate compliance to therapy twice with 4 week interval
Trial Locations
- Locations (2)
Research SIte
🇱🇻Cesis, Latvia
Research Site
🇱🇻Valmiera, Latvia